Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer).

The main purpose of this study is to compare how long patients with glioblastoma (GBM, a
malignant brain cancer) live after receiving temozolomide plus radiation therapy compared
with patients receiving nivolumab in addition to temozolomide plus radiation therapy.

Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Males and Females, age ≥ 18 years old

- Newly diagnosed brain cancer or tumor called glioblastoma or GBM

- Karnofsky performance status of ≥ 70 (able to take care of self)

- Substantial recovery from surgery resection

- Tumor test result shows MGMT methylated or indeterminate tumor subtype

Exclusion Criteria:

- Biopsy-only of GBM with less than 20% of tumor removed

- Prior treatment for GBM (other than surgical resection)

- Any known tumor outside of the brain

- Recurrent or secondary GBM

- Active known or suspected autoimmune disease

Other protocol defined inclusion/exclusion criteria could apply

Principal Investigator

Bristol-Myers Squibb

Study Contact

Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:, Clinical.Trials@bms.com

Estimated Completion Date

Tuesday, May 1, 2018

ClinicalTrials.gov #

NCT02667587
10/27/2016